recent initi
updat forecast includ mgt guidanc acquisit ranir
divestitur pet care busi reclassif sever segment base
addit invest restructur project discuss recent investor
day note weve lower ep est
respect without gener busi ep would pt
manag strategi restructur reinvigor growth make sens
although convinc divest far higher margin specialti gener
busi answer
management laid base assumpt newco follow plan separ
rx gener busi late earli inclus rx
busi see earn power current busi
potenti upsid launch gener proair
quarter cost save program project momentum inclus
ranir expect close assum divestitur gener busi
adjust ep dilut impact via spin management see base
earn new consum compani note updat
forecast includ prgo base assumpt well impact ranir
start assum upsid project momentum impact
manag target revenue/ep profil similar high perform cpg
management laid plan return current earn power next
year via organ growth cost save project
momentum captur save inde management success execut
plan believ could emerg profil similar high perform cpg
compar rev oper incom ep growth
leverag ratio scenario management hope share trade p/
 multipl closer cpg peer vs current point given
headwind compani continu face lack new product flow price pressur
etc see tall order team consist deliv particularli
organ growth time degre multipl expans order
proactiv move forward creat self-car focus consum
compani still concern recent tax assess irish
govern ir new pt vs
management alloc invest address suppli constraint
hinder growth busi priorit debt reduct bolt-on
primari use cash howev plan take reserv potenti
legaci tax liabil recent emerg believ
new assess valid may take number year resolv believ
financi restat reflect divestitur tysabri
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
still repres meaning risk new pt vs base
unchang updat ep estim
pleas see import disclosur inform page report
vertic integr global healthcar compani
develop manufactur distribut over-the-count
over-the-counter healthcar product gener rx drug co
largest global manufactur store brand privat label over-the-counter
pharmaceut product infant formula benefit
signific macro trend consum accept
store brand omega brand european over-the-counter busi
met expect plan separ divest
spin etc gener busi uncertain
unlock valu sharehold recent emerg legaci
tax liabil also concern
potenti extern pressur sharehold activ
take-over specul
new product launch chc busi rx over-the-counter
potenti bolt-on acquisit chc self
success p-iv challeng larg brand rx product
gener price improv base erod mid-singl
digit gener proair includ forecast
chca busi grow low single-digit rate driven new
product flow nexium nasonex over-the-counter launch expect
chci margin continu steadili expand
meaning growth d/new product success
develop self busi
chc segment realiz stronger anticip net sale
cost save restructur
litig win potenti earlier expect gener
chci return growth faster expect
gener price environ continu neg impact
chci remain drag prgo busi
lower anticip gross margin expans due
pleas see import disclosur inform page report
financi summari market data
estim valuat
financi restat reflect divestitur tysabri
pleas see import disclosur inform page report
